# Microbiome Co

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microbiome-2

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.microbiomekorea.co.kr
- Total disclosed funding: $1.6M
- Latest round: Series A (May 20, 2022)
- Investors on record: 3

## About

Founded in 2017, and based in Seoul, South Korea, Microbiome Inc. operates as a biotechnology company that researches and develops pharmaceutical, beauty, and alternative food products. In May 2022, Microbiome raised KRW 2 billion in Series A funding led by  investor New Paradigm Investment, with participation from KAIC and KMU Holdings.

The company focuses on microbiome research and development with a focus on microbiome regulation materials, addressing metabolic diseases, immune enhancement, and colorectal cancer. The firm also is involved in the research and development of microbiomes to address other healthcare and cosmetic challenges to offer healthcare improvements.

## Funding rounds

- Series A, May 20, 2022, $1.6M — New Paradigm Investment, Chung-Ang University KAIC, KMU Holdings

## Investors

- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Series A
- Chung-Ang University KAIC — Series A
- KMU Holdings — Series A